Elevated platelet counts are a common finding in many cancer patients, including patients with ovarian cancer. Patients with ovarian cancer and thrombocytosis have a worse prognosis compared to patients with similar stages of cancer and normal platelet counts. We have shown that platelets promote proliferation of cancer cells both in vitro and in the murine models of ovarian cancer;and reducing platelet counts decreased the size of orthotopic tumor induced in mice by ovarian cancer cells. To identify the mechanisms of the growth- enhancing effect of platelets on cancer cells, we used blocking reagents against platelets in vitro, and found that platelet activation and release of TGF?1 are important for the proliferative effect of platelets on cancer cells. In this project, we will study the interaction between platelets and cancer cells in vivo, using both murine models of ovarian cancer and tissue samples obtained from patients with ovarian cancer. Our hypothesis is that there is a feedback loop between platelets and cancer cells. Cancer cells secrete ADP and activate platelets, and platelets secrete TGF?1 that promotes proliferation in cancer cells. In the specific aim 1, we will investigate whether blocking ADP receptors on platelets would disrupt the growth promoting effect of platelets on orthotopic tumors in mice, using genetically modified mice or pharmacologic reagents. In the specific aim 2, we will target TGF?1 secretion from platelets, TGF?1 receptor on cancer cells, or TGF?1 receptor signaling to evaluate the role of TGF?1 on the platelet-cancer cell interaction. We will use platelet-specific TGF?1 deficient mice, inhibitor RNAs, or pharmacologic reagents against TGF? receptor signaling to conduct these experiments. For the interaction between platelets and cancer cells to occur inside the tumors, platelets should exit circulation and enter into tumor microenvironment. We have shown the presence of platelets outside of blood vessel inside the implanted tumors in mice. In the specific aim 3, we will study the mechanisms of platelet exit from tumor microcirculation using immunofluorescence and electron microscopy on human and murine ovarian cancer tissue samples. We will identify the route of platelet extravasation, and evaluate the dependency of platelets on neutrophils for extravasation. The goal of our studies in this grant proposal is to evaluate the possibility of using anti-platelet reagents as an effective anticancer therapy.

Public Health Relevance

Platelets promote growth and metastasis of malignant tumors. In this project, we will identify the mechanism of platelet involvement in tumor growth in murine models of ovarian cancer. We will investigate the effect of blocking the interaction between platelets and cancer cells, using available anti-platelet medications, on tumor progression with a long term goal to evaluate the usefulness of anti-platelet medications as an effective and relatively safe anti-cancer therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA177909-02
Application #
8706102
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2013-08-01
Project End
2018-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
2
Fiscal Year
2014
Total Cost
$322,040
Indirect Cost
$120,765
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Huang, Jie; Hu, Wei; Hu, Limin et al. (2016) Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol Cancer Ther 15:1344-52
Kang, Yu; Nagaraja, Archana S; Armaiz-Pena, Guillermo N et al. (2016) Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clin Cancer Res 22:1713-24
Cho, Min Soon; Rupaimoole, Rajesha; Choi, Hyun-Jin et al. (2016) Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition. J Immunol 196:1412-8
Nagaraja, A S; Dorniak, P L; Sadaoui, N C et al. (2016) Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis. Oncogene 35:2390-7
Mitamura, Takashi; Gourley, Charlie; Sood, Anil K (2016) Prediction of anti-angiogenesis escape. Gynecol Oncol 141:80-5
Feng, Shuju; Kroll, Michael H; Nick, Alpa M et al. (2016) Platelets are not hyperreactive in patients with ovarian cancer. Platelets 27:716-718
Rupaimoole, Rajesha; Calin, George A; Lopez-Berestein, Gabriel et al. (2016) miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov 6:235-46
Haemmerle, Monika; Bottsford-Miller, Justin; Pradeep, Sunila et al. (2016) FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 126:1885-96
Hu, Qianghua; Wang, Miao; Cho, Min Soon et al. (2016) Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. BBA Clin 6:76-81
Huang, Yan; Lichtenberger, Lenard M; Taylor, Morgan et al. (2016) Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Mol Cancer Ther 15:2894-2904

Showing the most recent 10 out of 41 publications